



ASX ANNOUNCEMENT

6 January 2021

## Results of Share Purchase Plan

CardieX Limited (ASX: CDX) (CardieX, the Company) is pleased to announce the successful completion of its Share Purchase Plan (SPP), which closed on 31 December 2020.

The Company received applications for fully paid ordinary shares (Shares) from eligible shareholders under the SPP at an issue price of \$0.05 per share in the amount of \$3.207 million (before costs) representing a 220% over-subscription over the target raise of \$1 million.

As disclosed in the SPP Offer Booklet (refer ASX release 7 December 2020), the Company reserved the right to conduct either a scale-back of over-subscriptions above \$1 million or to accept an amount higher than the target. In response to the strong demand from shareholders, the Company has elected to accept the full \$3.207 million of valid applications and not conduct any scale-back.

As previously announced, the Company intends for the funds raised under the SPP to be used primarily for working capital purposes and investment into the expansion of product and market development initiatives.

The Company expects allotment and issue of the SPP shares to occur on Tuesday, 12 January 2021 as per the previously announced timetable.

***Craig Cooper, CEO & Managing Director of CardieX commented:***

“We are very pleased with the support we have received under the SPP which is representative of the confidence that shareholders have in our growth plan and vision for the Company. This is the most that the Company has ever raised under an SPP at a time when innovation and leadership in healthcare and med-tech solutions are required more than ever. 2021 will be a defining year for us with multiple new products and digital solutions on track for launch during the period. I look forward to updating shareholders more on progress in the very near future”.

**Authorised for release by the Board of Directors, and released by Jarrod White**

For more information please contact:

**Investor Relations**

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

**Media Relations**

Melissa Hamilton

[melissa.hamilton@mcpartners.com](mailto:melissa.hamilton@mcpartners.com)



**About CardieX**

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR·X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).